A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation. The recommendations update the 2020 guideline from ASCO, the American Society for Radiation Oncology (ASTRO), and the Society of Surgical Oncology (SSO) published on the management of hereditary breast cancer.
ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.
To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.
The COVID-19 pandemic has profoundly interrupted delivery of key preventive services, resulting in many adolescents missing routine human papillomavirus (HPV) vaccine doses. In response, the American Society of Clinical Oncology (ASCO) and nearly 80 National Cancer Institute (NCI)-designated cancer centers and other organizations issued a joint statement urging the nation’s health care systems, physicians, parents and children, and young adults to get HPV vaccination back on track.
The American Society of Clinical Oncology (ASCO) issued a new position statement outlining the issues that telemedicine cross-state licensure presents for the cancer care community, in addition to ASCO’s recommendations to continue the practice during the COVID-19 pandemic and beyond.
A recording is now available of a virtual roundtable focused on achieving equity in precision cancer care. The event was hosted by the American Society of Clinical Oncology (ASCO).
The Improving Senior’s Timely Access to Care Act (H.R. 3173) was recently re-introduced in the U.S. House of Representatives by Reps. Suzan DelBene (WA), Mike Kelly (PA), Dr. Ami Bera (CA), and Larry Bucshon (IN). The bill aims to streamline prior authorization practices and reduce care delays within the Medicare Advantage (MA) program.
On May 10, 2021, the Department of Health and Human Services’ (HHS) Office for Civil Rights announced that its ban on sex discrimination once again includes a ban on discrimination on the basis of sexual orientation and gender identity. The move will reverse a final rule from June 2020 that established a narrowed definition of sex that protected against discrimination only on the basis of "biological sex."
The Association for Clinical Oncology (ASCO) submitted comments to a House Ways and Means Health Subcommittee hearing titled “Charting the Path Forward for Telehealth.” The comments convey ASCO’s views on how telehealth can better serve individuals with cancer and the oncology professionals who care for them.
In a continuation of their collaboration to increase clinical trial participation among patients from underrepresented racial and ethnic groups, the American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) today announced plans to test a research site assessment tool and implicit bias training program, both of which are designed to address one of the barriers to clinical trial participation: trials not routinely being offered by clinicians to eligible patients.
From April 12-16, U.S. members of the Association for Clinical Oncology (ASCO) participated in the 2021 ASCO Advocacy Summit, where 148 advocates from 44 states and the District of Columbia held 222 virtual meetings – the most ever held during an Advocacy Summit – with Members of Congress and staff to urge action on important policies to improve access to high-quality, equitable care for people with cancer.
Today, the Association for Clinical Oncology (ASCO) presented Senators Richard Burr (R-NC) and Ben Cardin (D-MD) with the annual Congressional Champion for Cancer Care Award in recognition of their ongoing commitment to legislation that improves the environment for cancer research, oncology practice, and the quality of care for patients. The award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their cancer care teams.
On Friday, April 9, ASCO and Friends of Cancer Research (Friends) co-hosted a live virtual event, which brought together experts from across the healthcare sector to discuss the recent release of the new ASCO-Friends recommendations for modernizing eligibility criteria to improve patient access and representation in cancer clinical trials. ASCO-Friends recommendations address five specific areas: treatment washout periods, concomitant medications, prior therapies, laboratory reference ranges and test intervals, and patient performance status.
The Association for Clinical Oncology (ASCO) is holding its 2021 ASCO Advocacy Summit Week of Action from April 12-16. During the Week of Action, ASCO members can visit ASCO’s easy-to-use ACT Network to quickly and efficiently contact their lawmakers to urge them to take action on cancer policy priorities.
Beginning April 1, additional savings may be available for new and current consumers who purchase health insurance on HealthCare.gov following passage of the American Rescue Plan. The Centers for Medicare & Medicaid Services (CMS) also extended access to the Special Enrollment Period (SEP) for the federally funded health insurance marketplace until August 15, to provide additional time for consumers to enroll or make changes to their coverage with the tax credits that become available April 1.
The Association for Clinical Oncology joined the Prevent Cancer Foundation® and more than 300 other organizations from across the country in signing a letter to convey support for the Medicare Multi-Cancer Early Detection Screening Coverage Act. The legislation would allow the Centers for Medicare & Medicaid Services to evaluate and cover multi-cancer early detection tests once they are approved by the Food and Drug Administration.
The American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) will jointly host a virtual meeting on April 9 to build on efforts to broaden eligibility criteria to make clinical trials more representative.